X / Twitter
Facebook
LinkedIn
Reddit
About Insilico
Insilico Medicine is an innovative biotechnology company founded in 2014 at Johns Hopkins University. It focuses on accelerating drug discovery and development by utilizing artificial intelligence across various fields, including biology, chemistry, and clinical development. The company operates its proprietary Pharma.AI platform, which integrates three key modules: Biology42 for drug target identification, Chemistry42 for designing small molecules, and Medicine42 for optimizing clinical trials.
With a global presence that includes the U.S., Greater China, Canada, and the Middle East, Insilico Medicine employs around 200 people. The company has advanced multiple AI-designed drug candidates into clinical trials, including a lead drug for idiopathic pulmonary fibrosis currently in Phase II. Insilico also licenses its AI platform to pharmaceutical and biotechnology companies, enhancing their drug discovery processes. The company has published over 80 peer-reviewed papers and holds more than 30 patent applications, showcasing its commitment to research and innovation in the field.
With a global presence that includes the U.S., Greater China, Canada, and the Middle East, Insilico Medicine employs around 200 people. The company has advanced multiple AI-designed drug candidates into clinical trials, including a lead drug for idiopathic pulmonary fibrosis currently in Phase II. Insilico also licenses its AI platform to pharmaceutical and biotechnology companies, enhancing their drug discovery processes. The company has published over 80 peer-reviewed papers and holds more than 30 patent applications, showcasing its commitment to research and innovation in the field.
No screenshot available
